4-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)but-3-yn-1-ol | 911397-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)but-3-yn-1-ol
• 英文别名: 4-[2-amino-4-chloro-7-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-but-3-yn-1-ol；4-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]but-3-yn-1-ol
• CAS: 911397-55-2
• 化学式: C₁₉H₂₀ClN₅O₂
• 分子量: 385.853
• InChiKey: IUDRMGNLGRKNHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  99.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)but-3-yn-1-ol 在 N,N-二甲基乙酰胺 甲酸 、 氯磺酰异氰酸酯 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 4-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethyl-pyridin-2-yl)-methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-but-3-ynyl sulfamate
  参考文献：
  名称：

  ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS

  摘要：

  炔基吡咯并[2,3-d]嘧啶及相关类似物被描述并证明具有作为热休克蛋白90（HSP90）抑制剂的效用，用于治疗和预防各种HSP90介导的疾病。还描述和声明了这类化合物的合成和使用方法。

  公开号：

  US20060223797A1
• 作为产物：
  描述：

  N-(4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 在 N-碘代丁二酰亚胺 、 copper(l) iodide 、 10% Pd/C 、 苄基三乙基氯化铵 、 水 、 potassium carbonate 、 N,N-二甲基苯胺 、 三苯基膦 、 zinc(II) chloride 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 1.34h， 生成 4-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)but-3-yn-1-ol
  参考文献：
  名称：

  EC144 Is a Potent Inhibitor of the Heat Shock Protein 90

  摘要：

  Alkyne 40, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor 14 (BIIB021) that completed phase II clinical trials. Alkyne 40 is more potent than 14 in an Hsp90 alpha binding assay (IC50 = 1.1 vs 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs 38 nM). In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qdx5). Under the same conditions, 14 stops tumor growth only at 120 mg/kg, and does not induce partial regressions. Thus, alkyne 40 is approximately 20-fold more efficacious than 14 in mice.

  DOI：

  10.1021/jm300810x

文献信息

• ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS
  申请人：Kasibhatla Srinivas Rao

  公开号：US20090318387A1

  公开（公告）日：2009-12-24

  Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

  本文描述了炔基吡咯并[2,3-d]嘧啶及其相关类似物，证明其作为热休克蛋白90（HSP90）抑制剂在治疗和预防各种HSP90介导的疾病中具有用途。同时还描述和声明了这些化合物的合成和使用方法。
• Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
  申请人：Conforma Therapeutics Corporation

  公开号：US07544672B2

  公开（公告）日：2009-06-09

  Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

  本文描述了炔基吡咯并[2,3-d]嘧啶及其相关类似物，证明其作为抑制热休克蛋白90（HSP90）的药物在治疗和预防各种HSP90介导的疾病中具有实用性。还描述和声明了这种化合物的合成和使用方法。
• ANTI-TUMOR METHODS USING MULTI DRUG RESISTANCE INDEPENDENT SYNTHETIC HSP90 INHIBITORS
  申请人：Conforma Therapeutics Corporation

  公开号：EP1937258A2

  公开（公告）日：2008-07-02
• Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
  申请人：Zhang Hong

  公开号：US20070105874A1

  公开（公告）日：2007-05-10

  The present invention provides a method of treating an individual having an HSP90 mediated disorder comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a synthetic heterocyclic HSP90 inhibitor, wherein the activity of the HSP90 inhibitor is substantially independent of multi drug resistance. In one embodiment, the activity of the HSP90 inhibitor is substantially independent of P-gp and MRP expression.
• US7544672B2
  申请人：——

  公开号：US7544672B2

  公开（公告）日：2009-06-09